About this Journal Submit a Manuscript Table of Contents
Mediators of Inflammation
Volume 2012 (2012), Article ID 476979, 6 pages
http://dx.doi.org/10.1155/2012/476979
Research Article

Association between Serum Neopterin and Inflammatory Activation in Chronic Kidney Disease

Departments of Nephrology and Translational and Regenerative Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India

Received 14 June 2012; Revised 11 July 2012; Accepted 11 July 2012

Academic Editor: Giamila Fantuzzi

Copyright © 2012 Ashok Kumar Yadav et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Huber, J. R. Batchelor, and D. Fuchs, “Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma,” Journal of Experimental Medicine, vol. 160, no. 1, pp. 310–316, 1984. View at Scopus
  2. G. Hoffmann, B. Wirleitner, and D. Fuchs, “Potential role of immune system activation-associated production of neopterin derivatives in humans,” Inflammation Research, vol. 52, no. 8, pp. 313–321, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Y. Lhee, H. Kim, J. J. Kwan, S. J. Soo, and B. L. Kyu, “The clinical significance of serum and urinary neopterin levels in several renal diseases,” Journal of Korean Medical Science, vol. 21, no. 4, pp. 678–682, 2006. View at Scopus
  4. W. E. Aulitzky, H. Tilg, D. Nicderwieser et al., “Comparison of serum neopterin levels and urinary neopterin excretion in renal allograft recipients,” Clinical Nephrology, vol. 29, no. 5, pp. 248–252, 1988. View at Scopus
  5. J. L. Fahey, J. M. G. Taylor, R. Detels et al., “The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1,” New England Journal of Medicine, vol. 322, no. 3, pp. 166–172, 1990. View at Scopus
  6. W. Halota, B. Jaruga, and M. Pawłkowska, “Serum neopterin and β2-microglobulin concentration as 'prognostic markers' of AIDS natural history,” Polski Merkuriusz Lekarski, vol. 13, no. 74, pp. 126–128, 2002. View at Scopus
  7. C. Y. Lin, “Urinary neopterin as a new biochemical marker for the monitoring of disease activity and prognosis in membranous nephropathy associated with hepatitis B surface antigenemia,” Nephron, vol. 53, no. 2, pp. 115–120, 1989. View at Scopus
  8. W. Aulitzky, J. Frick, and D. Fuchs, “Significance of urinary neopterin in patients with malignant tumors of the genitourinary tract,” Cancer, vol. 55, no. 5, pp. 1052–1055, 1985. View at Scopus
  9. A. Bichler, D. Fuchs, and A. Hausen, “Urinary neopterine excretion in patients with genital cancer,” Clinical Biochemistry, vol. 15, no. 1, pp. 38–40, 1982. View at Scopus
  10. H. F. Alber, C. Duftner, M. Wanitschek et al., “Neopterin, CD4+CD28- lymphocytes and the extent and severity of coronary artery disease,” International Journal of Cardiology, vol. 135, no. 1, pp. 27–35, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. G. K. Chin, C. L. Adams, B. S. Carey, S. Shaw, W. Y. Tse, and E. R. Kaminski, “The value of serum neopterin, interferon-gamma levels and interleukin-12B polymorphisms in predicting acute renal allograft rejection,” Clinical and Experimental Immunology, vol. 152, no. 2, pp. 239–244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Gupta, S. Fredericks, R. A. Schwartzman et al., “Serum neopterin in acute coronary syndromes,” Lancet, vol. 349, no. 9060, pp. 1252–1253, 1997. View at Scopus
  13. M. Schumacher, G. Halwachs, F. Tatzber et al., “Increased neopterin in patients with chronic and acute coronary syndromes,” Journal of the American College of Cardiology, vol. 30, no. 3, pp. 703–707, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. M. F. Weiss, R. A. Rodby, A. C. Justice et al., “Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy,” Kidney International, vol. 54, no. 1, pp. 193–202, 1998. View at Scopus
  15. J. Auer, R. Berent, E. Lassnig, T. Weber, and B. Eber, “Prognostic significance of immune activation after acute coronary syndromes,” Journal of the American College of Cardiology, vol. 39, no. 11, p. 1878, 2002. View at Scopus
  16. M. Erren, H. Reinecke, R. Junker et al., “Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 10, pp. 2355–2363, 1999. View at Scopus
  17. T. Sasaki, Y. Takeishi, S. Suzuki et al., “High serum level of neopterin is a risk factor of patients with heart failure,” International Journal of Cardiology, vol. 145, no. 2, p. 318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Hermus, J. H. N. Schuitemaker, R. A. Tio et al., “Novel serum biomarkers in carotid artery stenosis: useful to identify the vulnerable plaque?” Clinical Biochemistry, vol. 44, no. 16, pp. 1292–1298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Avci, Ş. Coşkun, E. Çakir, Y. Kurt, E. Ö. Akgül, and C. Bilgi, “Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients,” Renal Failure, vol. 30, no. 8, pp. 784–790, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Kalantar-Zadeh, “Inflammatory marker mania in chronic kidney disease: Pentraxins at the crossroad of universal soldiers of inflammation,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 5, pp. 872–875, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Stenvinkel, “Inflammation in end-stage renal failure: could it be treated?” Nephrology Dialysis Transplantation, vol. 17, supplement 8, pp. 33–38, 2002. View at Scopus
  23. P. Stenvinkel, “Inflammation in end-stage renal disease—a fire that burns within,” Contributions to Nephrology, vol. 149, pp. 185–199, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. R. M. Bologa, D. M. Levine, T. S. Parker et al., “Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients,” American Journal of Kidney Diseases, vol. 32, no. 1, pp. 107–114, 1998. View at Scopus
  25. P. L. Kimmel, T. M. Phillips, S. J. Simmens et al., “Immunologic function and survival in hemodialysis patients,” Kidney International, vol. 54, no. 1, pp. 236–244, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Fuchs, A. Hausen, G. Reibnegger, E. R. Werner, V. P. Dittrich, and H. Wachter, “Neopterin levels in long-term hemodialysis,” Clinical Nephrology, vol. 30, no. 4, pp. 220–224, 1988. View at Scopus
  27. K. Godai, J. Uemasu, and H. Kawasaki, “Clinical significance of serum and urinary neopterins in patients with chronic renal disease,” Clinical Nephrology, vol. 36, no. 3, pp. 141–146, 1991. View at Scopus
  28. K. Oda, T. Arai, and M. Nagase, “Increased serum and urinary neopterin in nephrotic syndrome indicate cell-mediated immune dysfunction,” American Journal of Kidney Diseases, vol. 34, no. 4, pp. 611–617, 1999. View at Scopus
  29. A. K. Yadav and V. Jha, “CD4+CD28null cells are expanded and exhibit a cytolytic profile in end-stage renal disease patients on peritoneal dialysis,” Nephrology Dialysis Transplantation, vol. 26, no. 5, pp. 1689–1694, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. A. K. Yadav, A. Lal, and V. Jha, “Association of circulating fractalkine (CX3CL1) and CX3CR1(+)CD4(+) T cells with common carotid artery intima-media thickness in patients with chronic kidney disease,” Journal of Atherosclerosis and Thrombosis, vol. 18, no. 11, pp. 958–965, 2011. View at Scopus
  31. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999. View at Scopus
  32. National Kidney Foundation, “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, supplement, no. 2, pp. S1–S266, 2002. View at Publisher · View at Google Scholar
  33. R. Pecoits-Filho, O. Heimbürger, P. Bárány et al., “Associations between circulating inflammatory markers and residual renal function in CRF patients,” American Journal of Kidney Diseases, vol. 41, no. 6, pp. 1212–1218, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Jairam, R. Das, P. K. Aggarwal et al., “Iron status, inflammation and hepcidin in ESRD patients: the confounding role of intravenous iron therapy,” Indian Journal of Nephrology, vol. 20, no. 3, pp. 125–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Pecoits-Filho, P. Bárány, B. Lindholm, O. Heimbürger, and P. Stenvinkel, “Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment,” Nephrology Dialysis Transplantation, vol. 17, no. 9, pp. 1684–1688, 2002. View at Scopus
  36. C. K. Chiang, S. P. Hsu, M. F. Pai et al., “Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 19, no. 11, pp. 2810–2815, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. D. N. Reddan, P. S. Klassen, L. A. Szczech et al., “White blood cells as a novel mortality predictor in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 18, no. 6, pp. 1167–1173, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Zoccali, F. Mallamaci, G. Tripepi et al., “Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure,” Journal of Internal Medicine, vol. 254, no. 2, pp. 132–139, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Stenvinkel, O. Heimburger, T. Wang, B. Lindholm, J. Bergstrom, and G. Elinder, “High serum hyaluronan indicates poor survival in renal replacement therapy,” American Journal of Kidney Diseases, vol. 34, no. 6, pp. 1083–1088, 1999. View at Scopus
  40. J. Zimmermann, S. Herrlinger, A. Pruy, T. Metzger, and C. Wanner, “Inflammation enhances cardiovascular risk and mortality in hemodialysis patients,” Kidney International, vol. 55, no. 2, pp. 648–658, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Tong, J. J. Carrero, A. R. Qureshi et al., “Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 5, pp. 889–897, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. M. W. N. Nijsten, E. R. De Groot, H. J. Ten Duis, H. J. Klasen, C. E. Hack, and L. A. Aarden, “Serum levels of interleukin-6 and acute phase responses,” Lancet, vol. 2, no. 8564, p. 921, 1987. View at Scopus
  43. D. R. Schultz and P. I. Arnold, “Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, α1-acid glycoprotein, and fibrinogen,” Seminars in Arthritis and Rheumatism, vol. 20, no. 3, pp. 129–147, 1990. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Zaoui and R. M. Hakim, “The effects of the dialysis membrane on cytokine release,” Journal of the American Society of Nephrology, vol. 4, no. 9, pp. 1711–1718, 1994. View at Scopus
  45. E. R. Werner, G. Werner-Felmayer, D. Fuchs et al., “Biochemistry and function of pteridine synthesis in human and murine macrophages,” Pathobiology, vol. 59, no. 4, pp. 276–279, 1991. View at Scopus
  46. X. Garcia-Moll, F. Coccolo, D. Cole, and J. C. Kaski, “Serum Neopterin and complex stenosis morphology in patients with unstable angina,” Journal of the American College of Cardiology, vol. 35, no. 4, pp. 956–962, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Zouridakis, P. Avanzas, R. Arroyo-Espliguero, S. Fredericks, and J. C. Kaski, “Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris,” Circulation, vol. 110, no. 13, pp. 1747–1753, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. E. R. Pedersen, Ø. Midttun, P. M. Ueland et al., “Systemic markers of interferon-γ-mediated immune activation and long-term prognosis in patients with stable coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 3, pp. 698–704, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. W. Schobersberger, G. Hoffmann, J. Grote, H. Wachter, and D. Fuchs, “Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth muscle cells,” FEBS Letters, vol. 377, no. 3, pp. 461–464, 1995. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Werner-Felmayer, E. R. Werner, D. Fuchs et al., “Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide- mediated formation of cyclic GMP,” Journal of Biological Chemistry, vol. 268, no. 3, pp. 1842–1846, 1993. View at Scopus